United Therapeutics Corporation (UTHR)

United Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	3,078	2,877	2,328	1,936	1,686	1,483
Revenue	3,078	2,877	2,328	1,936	1,686	1,483
Revenue Growth (YoY)	17.62%	23.63%	20.20%	14.88%	13.63%	2.38%
Cost of Revenue	339.1	309.7	257.5	151.6	122.5	108.1
Gross Profit	2,739	2,568	2,070	1,785	1,563	1,375
Selling, General & Admin	701	640.4	476	472.8	466.1	421.1
Research & Development	520.3	481	408	322.9	410	357.7
Operating Expenses	1,221	1,121	884	795.7	876.1	778.8
Operating Income	1,517	1,446	1,186	989	686.9	596.4
Interest Expense	-31.4	-42.9	-59.3	-32.4	-18.6	-23.5
Interest & Investment Income	201.5	199.1	162.7	45.2	16.7	28.6
Other Non Operating Income (Expenses)	6.9	-1.4	-27.3	-38.3	43.8	26.4
EBT Excluding Unusual Items	1,694	1,601	1,262	963.5	728.8	627.9
Gain (Loss) on Sale of Investments	-6.3	9	15.8	-1.7	-2.3	16.4
Asset Writedown	-	-	-3.6	-11.2	-132.6	-5.4
Legal Settlements	-71.1	-71.1	-	-	-	-
Pretax Income	1,617	1,539	1,274	950.6	593.9	638.9
Income Tax Expense	374.9	343.9	289.5	223.3	118.1	124.1
Net Income	1,242	1,195	984.8	727.3	475.8	514.8
Net Income to Common	1,242	1,195	984.8	727.3	475.8	514.8
Net Income Growth	16.15%	21.36%	35.41%	52.86%	-7.58%	-
Shares Outstanding (Basic)	45	45	47	46	45	44
Shares Outstanding (Diluted)	48	49	50	49	47	45
Shares Change (YoY)	-1.52%	-2.41%	2.47%	2.54%	6.05%	1.83%
EPS (Basic)	27.69	26.44	21.04	15.98	10.60	11.65
EPS (Diluted)	25.63	24.64	19.81	15.00	10.06	11.54
EPS Growth	17.94%	24.38%	32.07%	49.10%	-12.83%	-
Free Cash Flow	1,071	1,081	747.6	663.7	477.4	696.4
Free Cash Flow Per Share	22.11	22.28	15.04	13.69	10.09	15.61
Gross Margin	88.98%	89.24%	88.94%	92.17%	92.73%	92.71%
Operating Margin	49.30%	50.26%	50.96%	51.08%	40.75%	40.21%
Profit Margin	40.36%	41.53%	42.31%	37.56%	28.23%	34.71%
Free Cash Flow Margin	34.80%	37.55%	32.12%	34.28%	28.32%	46.95%
EBITDA	1,597	1,519	1,239	1,040	736.8	646.3
EBITDA Margin	51.89%	52.78%	53.24%	53.73%	43.71%	43.57%
D&A For EBITDA	79.7	72.5	53.2	51.3	49.9	49.9
EBIT	1,517	1,446	1,186	989	686.9	596.4
EBIT Margin	49.30%	50.26%	50.96%	51.08%	40.75%	40.21%
Effective Tax Rate	23.18%	22.35%	22.72%	23.49%	19.89%	19.42%

Updated Jul 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q